Robert J. van Soest

Efficacy of Cabazitaxel in Castration-resistant Prostate Cancer Is Independent of the Presence of AR-V7 in Circulating Tumor Cells

Wendy Onstenk, Anieta M. Sieuwerts, Jaco Kraan et al. · European Urology · 2015 · 237 citations

Urology, Oncology, Genitourinary Cancer +8

Cross-resistance between taxanes and new hormonal agents abiraterone and enzalutamide may affect drug sequence choices in metastatic castration-resistant prostate cancer

Robert J. van Soest, Martin E. van Royen, Ellen S. de Morrée et al. · European Journal of Cancer · 2013 · 203 citations

Urology, Oncology, Medicine +7

Neutrophil-to-lymphocyte ratio as a prognostic biomarker for men with metastatic castration-resistant prostate cancer receiving first-line chemotherapy: data from two randomized phase III trials

Robert J. van Soest, Arnoud J. Templeton, Francisco Vera-Badillo et al. · Annals of Oncology · 2014 · 138 citations · Full text

Targeting the Androgen Receptor Confers In Vivo Cross-resistance Between Enzalutamide and Docetaxel, But Not Cabazitaxel, in Castration-resistant Prostate Cancer

Robert J. van Soest, Ellen S. de Morrée, Charlotte F. Kweldam et al. · European Urology · 2014 · 130 citations

Urology, Medicine, Pharmacology +9

Loss of SLCO1B3 drives taxane resistance in prostate cancer

Ellen S. de Morrée, René Böttcher, Robert J. van Soest et al. · British Journal of Cancer · 2016 · 64 citations · Full text